Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus

Journal of the American Society of Nephrology

Volumn 16, Issue 10, 2005, Pages 3128-3135

  Teutonico, Annalisa ^a   Schena, Paolo F ^a   Di Paolo, Salvatore ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; RAPAMYCIN; TSUKUBAENOLIDE; CALCINEURIN; CYCLOSPORIN; GLUCOSE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SUBSTITUTION; GLUCOSE METABOLISM; GRAFT RECIPIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; KIDNEY TRANSPLANTATION; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL; ADULT; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; KIDNEY; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; CALCINEURIN; CYCLOSPORINE; FEMALE; GLUCOSE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIROLIMUS;

EID: 32844474879     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005050487     Document Type: Article

References (48)

1. Weir MR, Fink JC: Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 34: 1-13, 1999
2. Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM: Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 62: 1440-1446, 2002
3. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC: Posttransplantation diabetes: A systematic review of the literature. Diabetes Care 25: 583-592, 2002
4. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3: 178-185, 2003
5. Hjelmesaeth J, Hagen M, Hartmann A, Midtvedt K, Egeland T, Jenssen T: The impact of impaired insulin release and insulin resistance on glucose intolerance after renal transplantation. Clin Transplant 16: 389-396, 2002
6. van Hooff JP, Christiaans MH, van Duijnhoven EM: Evaluating mechanisms of post-transplant diabetes mellitus. Nephrol Dial Transplant 19[Suppl 6]: 8-12, 2004
7. Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernandez D, Kasiske BL, Kiberd B, Krentz A, Legendre C, Marchetti P, Markell M, van der Woude FJ, Wheeler D: Diabetes after transplantation: 2003 International Consensus Guidelines. Transplantation 75: SS3-SS24, 2003
8. Midtvedt K, Hjelmesaeth J, Hartmann A, Lund K, Paulsen D, Egeland T, Jenssen T: Insulin resistance after renal transplantation: The effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 15: 3233-3239, 2004
9. Heisel O, Heisel R, Balshaw R, Keown P: New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis. Am J Transplant 4: 583-595, 2004
10. Hricik DE: Use of sirolimus to facilitate cyclosporine avoidance or steroid withdrawal in kidney transplant recipients. Transplant Proc 35[Suppl]: 73-78, 2003
11. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, Burke JT, Brault Y, Gioud-Paquet M, Scarola JA, Neylan JF; Rapamune Maintenance Regimen Trial: Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15: 809-817, 2004
12. Mota A, Arias M, Taskinen EI, Paavonen T, Brault Y, Legendre C, Claesson K, Castagneto M, Campistol JM, Hutchison B, Burke JT, Yilmaz S, Hayry P, Neylan JF: Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 4: 953-961, 2004
13. Kahan BD: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study: The Rapamune US Study Group. Lancet 356: 194-202, 2000
14. MacDonald AS; The RAPAMUNE Global Study Group: A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71: 271-280, 2001
15. Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattstrom C, Lebranchu Y, Vialtel P: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69: 1252-1260, 2000
16. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72: 777-786, 2001
17. Stallone G, Di Paolo S, Schena A, Infante B, Battaglia M, Ditonno P, Gesualdo L, Grandaliano G, Schena FP: Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol 15: 228-233, 2004
18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26[SuppI 1]: S5-S20, 2003
19. Hjelmesaeth J, Midtvedt K, Jenssen T, Hartmann A: Insulin resistance after renal transplantation: Impact of immunosuppressive and antihypertensive therapy. Diabetes Care 24: 2121-2126, 2001
20. Bonora E, Moghetti P, Zancanaro C, Cigolini M, Querena M, Cacciatori V, Corgnati A, Muggeo M: Estimates of in vivo insulin action in man: Comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab 68: 374-378, 1989
21. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften T, Renn W, Gerich J: Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23: 295-301, 2000
22. Bergman RN, Ader M, Huecking K, Van Gitters G: Accurate assessment of beta-cell function. The hyperbolic correction. Diabetes 51[Suppl]: 212-220, 2002
23. Hjelmesaeth J, Jenssen T, Hagen M, Egeland T, Hartmann A: Determinants of insulin secretion after renal transplantation. Metabolism 52: 573-578, 2003
24. Lewis GF, Carpentier A, Adeli K, Giacca A: Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23: 201-229, 2002
25. Shi Y, Taylor SI, Tan SL, Sonenberg N: When translation meets metabolism: Multiple links to diabetes. Endocr Rev 24: 91-101, 2003
26. Harrington LS, Findlay GM, Lamb RF: Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 30: 35-42, 2005
27. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, Thomas G: Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431: 200-205, 2004
28. Nam JH, Mun JI, Kim SI, Kang SW, Choi KH, Park K, Ahn CW, Cha BS, Song YD, Lim SK, Kim KR, Lee HC, Huh KB: Beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 71: 1417-1423, 2001
29. van Duijnhoven EM, Christiaans MH, Boots JM, Nieman FH, Wolffenbuttel BH, van Hooff JP: Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 13: 213-220, 2002
30. Boots JM, van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, van Hooff JP: Glucose metabolism in renal transplant recipients on tacrolimus: The effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 13: 221-227, 2002
31. Syed NA, Khandelwal RL: Reciprocal regulation of glycogen phosphorylase and glycogen synthase by insulin involving phosphatidylinositol-3 kinase and protein phosphatase-1 in HepG2 cells. Mol Cell Biochem 211: 123-136, 2000
32. Liu Z, Wu Y, Nicklas EW, Jahn LA, Price WJ, Barrett EJ: Unlike insulin, amino acids stimulate p70S6K but not GSK-3 or glycogen synthase in human skeletal muscle. Am J Physiol Endocrinol Metab 286: E523-E528, 2004
33. Taha C, Liu Z, Jin J, Al-Hasani H, Sonenberg N, Klip A: Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin. Role of mammalian target of rapamycin, protein kinase b, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation. J Biol Chem 274: 33085-33091, 1999
34. Rhodes CJ, White MF: Molecular insights into insulin action and secretion. Eur J Clin Invest 32[Suppl 3]: 3-13, 2002
35. Paty BW, Harmon JS, Marsh CL, Robertson RP: Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. Transplantation 73: 353-357, 2002
36. Briaud I, Lingohr MK, Dickson LM, Wrede CE, Rhodes CJ: Differential activation mechanisms of Erk-1/2 and p70(S6K) by glucose in pancreatic beta-cells. Diabetes 52: 974-983, 2003
37. Andoh TF, Lindsley J, Franceschini N, Bennett WM: Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 62: 311-316, 1996
38. Hricik DE, Anton HA, Knauss TC, Rodriguez V, Seaman D, Siegel C, Valente J, Schulak JA: Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. Transplantation 74: 189-193, 2002
39. Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roth D, Kupin W, Nicolas M, Ruiz P, Rosen A, Miller J: A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 77: 252-258, 2004
40. Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ: Isolated post-challenge hyperglycemia confirmed as a risk factor for mortality. Diabetologia 42: 1050-1054, 1999
41. The DECODE Study Group: Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria: European Diabetes Epidemiology Group: Diabetes Epidemiology: Collaborative Analysis of Diagnostic criteria in Europe. Lancet 354: 617-621, 1999
42. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: The Funagata Diabetes Study. Diabetes Care 22: 920-924, 1999
43. Cosio FG, Kudva Y, Velde M, Larson TS, Textor SC, Griffin MD, Stegall MD: New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 67: 2415-2421, 2005
44. Markell M: New-onset diabetes mellitus in transplant patients: Pathogenesis, complications, and management. Am J Kidney Dis 43: 953-965, 2004
45. Berg CE, Lavan BE, Rondinone CM: Rapamycin partially prevents insulin resistance induced by chronic insulin treatment. Biochem Biophys Res Commun 293: 1021-1027, 2002
46. Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ, Opekun AR, Jaffe JS, Oppermann S, Kahan BD: Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 43: 1170-1180, 2002
47. Sechi LA, Catena C, Zingaro L, Melis A, De Marchi S: Abnormalities of glucose metabolism in patients with early renal failure. Diabetes 51: 1226-1232, 2002
48. Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, Ritz E: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 53: 1343-1347, 1998